NRx Pharmaceuticals Receives Final Approval to Acquire Dura Medical, Enhancing Mental Health Services in Florida

NRx Pharmaceuticals has received final clearance from Florida's Agency for Health Care Administration to close the acquisition of Dura Medical, a revenue-generating healthcare provider. The acquisition will enhance HOPE Therapeutics' presence in Florida's mental health services sector and boost NRx Pharmaceuticals' operational and financial performance. Dura Medical offers advanced treatments for depression, PTSD, and related disorders and aims to treat over 10,000 patients by 2026.

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have received final clearance from Florida's Agency for Health Care Administration (AHCA) to proceed with the closing of the Dura Medical acquisition. This regulatory approval marks a significant step towards the integration of Dura Medical into HOPE Therapeutics' network, which will expand its mental health services in Florida and enhance NRx Pharmaceuticals' operational and financial performance.

Dura Medical, founded in 2018, specializes in providing precision psychiatry services for severe depression, PTSD, and related CNS disorders. The company offers a range of advanced treatments, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato®, and Stellate Ganglion Blocks, alongside traditional psychiatry and therapy. The acquisition will enable HOPE Therapeutics to expand its services along the West Coast of Florida, aiming to treat over 10,000 patients by 2026.

The acquisition is expected to be accretive to revenue and EBITDA, indicating that it will contribute positively to the financial performance of both HOPE Therapeutics and NRx Pharmaceuticals. This is a significant milestone for NRx Pharmaceuticals, which is developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD.

The final clearance from AHCA is a critical regulatory step towards closing the acquisition, which is subject to standard closing conditions. Dura Medical has been revenue-generating and EBITDA positive, making it an attractive addition to HOPE Therapeutics' network. The acquisition will allow HOPE Therapeutics to leverage Dura Medical's expertise in advanced mental health treatments and expand its services to veterans and civilians alike.

Stephen Durand, Founder of Dura Medical, expressed his excitement about the alignment of his mission with HOPE Therapeutics' expansion in Florida and beyond. Jonathan Javitt, MD, MPH, and Matthew Duffy, Co-CEOs of HOPE Therapeutics, also welcomed the clearance and highlighted the potential for Dura Medical's tradition of excellence and commitment to patient care to be integrated into HOPE's network.

For further information, contact:
Matthew Duffy, Co-CEO, HOPE Therapeutics, Inc. (917) 653-5122, mduffy@nrxpharma.com
Brian Korb, Managing Partner, Astr Partners, brian.korb@astrpartners.com

References:
[1] https://www.morningstar.com/news/pr-newswire/20250808cl47175/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-receipt-of-final-clearance-to-proceed-to-closing-of-dura-medical-acquisition-from-floridas-agency-for-health-care-administration-ahca